Secondary Hyperparathyroidism - Epidemiology Forecast to 2027

Secondary Hyperparathyroidism - Epidemiology Forecast to 2027

Category

Pharmaceuticals

Published Date

1st Feb 2018

Pages

50

Choose License

Final Price

DelveInsight's "Secondary Hyperparathyroidism - Epidemiology Forecast, 2027” report provides a comprehensive analysis of the Secondary Hyperparathyroidism epidemiology, providing the historical and forecasted data for the 7MM during the forecast period from 2016-2027.

Markets Covered
• United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2016-2027

Secondary Hyperparathyroidism Epidemiology
The epidemiology section covers the historical, current as well as forecasted epidemiology for Secondary Hyperparathyroidism in 7 major markets. The data is collected by understanding the disease, reviewing numerous studies conducted by countries and by exploring different surveys as well as reports. The Key opinion leaders’ views are also taken into account to provide a deep understanding of the Secondary Hyperparathyroidism outlook. It also includes the explanation of changing trends of epidemiology outlining the Secondary Hyperparathyroidism scenario.

Secondary Hyperparathyroidism Epidemiology Segmentation
The epidemiology section is further segmented according to the patient pool characteristics, such as age-specific, type-specific, sub-type specific, gender-specific etc., thus providing an in-depth and high-quality analysis. The report also covers the prevalent/Incidence cases as well as the treatable cases as per the therapies available for the Secondary Hyperparathyroidism thereby presenting the trends with detailed analysis, with the assumptions undertaken. The data is presented in the form of graphs along with tables to effectively summarize the landscape.

Report Scope
• The report covers detailed overview of Secondary Hyperparathyroidism explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
• It provides the insight about the historical and forecasted patient pool for 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan
• The Secondary Hyperparathyroidism Report assesses the disease risk and burden and highlights the unmet needs
• It also helps to recognize the growth opportunities in the 7MM with respect to the patient population

Key strengths
• 10 Year Forecast
• 7MM Coverage
• Total Cases in Secondary Hyperparathyroidism

Key assessments
• Patient Segmentation in Secondary Hyperparathyroidism
• Secondary Hyperparathyroidism Risk & Burden
• Factors driving growth in a specific Secondary Hyperparathyroidism patient population
1. Report Introduction
2. Secondary Hyperparathyroidism Epidemiology Overview at a Glance
2.1. Patient Share Distribution of Secondary Hyperparathyroidism in 2017
2.2. Patient Share Distribution of Secondary Hyperparathyroidism in 2027
3. Disease Background and Overview: Secondary Hyperparathyroidism
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Secondary Hyperparathyroidism in 7MM
4.3. Total Prevalent/ Incident Patient Population of Secondary Hyperparathyroidism in 7MM – By Countries
5. Epidemiology of Secondary Hyperparathyroidism by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Secondary Hyperparathyroidism
5.1.3. Sub-Type Specific cases of the Secondary Hyperparathyroidism *
5.1.4. Sex- Specific Cases of the Secondary Hyperparathyroidism *
5.1.5. Diagnosed Cases of the Secondary Hyperparathyroidism
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Secondary Hyperparathyroidism
5.4.3. Sub-Type Specific cases of the Secondary Hyperparathyroidism *
5.4.4. Sex- Specific Cases of the Secondary Hyperparathyroidism *
5.4.5. Diagnosed Cases of the Secondary Hyperparathyroidism
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Secondary Hyperparathyroidism
5.5.3. Sub-Type Specific cases of the Secondary Hyperparathyroidism *
5.5.4. Sex- Specific Cases of the Secondary Hyperparathyroidism *
5.5.5. Diagnosed Cases of the Secondary Hyperparathyroidism
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Secondary Hyperparathyroidism
5.6.3. Sub-Type Specific cases of the Secondary Hyperparathyroidism *
5.6.4. Sex- Specific Cases of the Secondary Hyperparathyroidism *
5.6.5. Diagnosed Cases of the Secondary Hyperparathyroidism
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Secondary Hyperparathyroidism
5.7.3. Sub-Type Specific cases of the Secondary Hyperparathyroidism *
5.7.4. Sex- Specific Cases of the Secondary Hyperparathyroidism *
5.7.5. Diagnosed Cases of the Secondary Hyperparathyroidism
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Secondary Hyperparathyroidism
5.8.3. Sub-Type Specific cases of the Secondary Hyperparathyroidism *
5.8.4. Sex- Specific Cases of the Secondary Hyperparathyroidism *
5.8.5. Diagnosed Cases of the Secondary Hyperparathyroidism
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Secondary Hyperparathyroidism
5.9.3. Sub-Type Specific cases of the Secondary Hyperparathyroidism *
5.9.4. Sex- Specific Cases of the Secondary Hyperparathyroidism *
5.9.5. Diagnosed Cases of the Secondary Hyperparathyroidism
6. Unmet Needs of the Secondary Hyperparathyroidism
7. Appendix
8. Report Methodology
8.1. Sources
9. DelveInsight Capabilities
10. Disclaimer
11. About DelveInsight
*Indication Specific
Table 1: Total Prevalent/Incident Cases of the Secondary Hyperparathyroidism in 7MM
Table 2: Total Prevalent/Incident Cases of the Secondary Hyperparathyroidism in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Secondary Hyperparathyroidism in United States (2016-2027)
Table 4: Sub-Type Specific cases of the Secondary Hyperparathyroidism in United States (2016-2027)*
Table 5: Sex- Specific Cases of the Secondary Hyperparathyroidism in United States (2016-2027)*
Table 6: Diagnosed Cases of the Secondary Hyperparathyroidism in United States (2016-2027)
Table 7: Prevalent/Incident Cases of the Secondary Hyperparathyroidism in Germany (2016-2027)
Table 8: Sub-Type Specific cases of the Secondary Hyperparathyroidism in Germany (2016-2027) *
Table 9: Sex- Specific Cases of the Secondary Hyperparathyroidism in Germany (2016-2027) *
Table 10: Diagnosed Cases of the Secondary Hyperparathyroidism in Germany (2016-2027)
Table 11: Prevalent/Incident Cases of the Secondary Hyperparathyroidism in France (2016-2027)
Table 12: Sub-Type Specific cases of the Secondary Hyperparathyroidism in France (2016-2027) *
Table 13: Sex- Specific Cases of the Secondary Hyperparathyroidism in France (2016-2027) *
Table 14: Diagnosed Cases of the Secondary Hyperparathyroidism in France (2016-2027)
Table 15: Prevalent/Incident Cases of the Secondary Hyperparathyroidism in Italy (2016-2027)
Table 16: Sub-Type Specific cases of the Secondary Hyperparathyroidism in Italy (2016-2027) *
Table 17: Sex- Specific Cases of the Secondary Hyperparathyroidism in Italy (2016-2027) *
Table 18: Diagnosed Cases of the Secondary Hyperparathyroidism in Italy (2016-2027)
Table 19: Prevalent/Incident Cases of the Secondary Hyperparathyroidism in Spain (2016-2027)
Table 20: Sub-Type Specific cases of the Secondary Hyperparathyroidism in Spain (2016-2027) *
Table 21: Sex- Specific Cases of the Secondary Hyperparathyroidism in Spain (2016-2027) *
Table 22: Diagnosed Cases of the Secondary Hyperparathyroidism in Spain (2016-2027)
Table 23: Prevalent/Incident Cases of the Secondary Hyperparathyroidism in UK (2016-2027)
Table 24: Sub-Type Specific cases of the Secondary Hyperparathyroidism in UK (2016-2027) *
Table 25: Sex- Specific Cases of the Secondary Hyperparathyroidism in UK (2016-2027) *
Table 26: Diagnosed Cases of the Secondary Hyperparathyroidism in UK (2016-2027)
Table 27: Prevalent/Incident Cases of the Secondary Hyperparathyroidism in Japan (2016-2027)
Table 28: Sub-Type Specific cases of the Secondary Hyperparathyroidism in Japan (2016-2027) *
Table 29: Sex- Specific Cases of the Secondary Hyperparathyroidism in Japan (2016-2027) *
Table 30: Diagnosed Cases of the Secondary Hyperparathyroidism in Japan (2016-2027)

Get Free Sample

You can get a FREE sample of any report. Just click the "Free Sample" link.

Explore Latest Reports

If you have any special requirement or looking for more discounts, Kindly contact our sales team

Contact Us